Table 3.
Comparison of Schizophrenia Subjects from Three-Class Growth Mixture
| Variable | All SCZ (N=201) |
Class 1 (N=101) |
Class 2 (N=81) |
Class 3 (N=19) |
|
|---|---|---|---|---|---|
| Mean (SD) | Mean (SD) | Mean (SD) | Mean (SD) | F-test (df1/df2); p-value | |
| Baseline Age | 57.7(8.5) | 56.7(7.8) | 58.2 (8.9) | 60.9 (9.0) | 2.2 (2,198); .111 |
| Education | 12.7(2.6) | 13.2(2.3) | 12.4(2.7) | 10.9(3.1) | 47.6 (2,198); <.001 |
| PANSS* | |||||
| Negative | 14.3 (5.7) | 13.1(5.1) | 14.3 (4.6) | 20.6(8.1) | 13.6 (2,153); <.001 |
| Positive | 13.8(5.3) | 13.3 (5.4) | 14.1 (5.5) | 14.6 (3.4) | .6 (2,153); .573 |
| Total | 56.3 (15.3) | 53.4(14.1) | 56.7 (14.4) | 68.1 (18.9) | 6.6 (2,153); .002 |
| Age of Onset | 30.9(13.2) | 31.1(13.8) | 30.1 (11.6) | 33.2(15.9) | .4 (2,177) .661 |
| Duration of | 27.1 (13.5) | 26.0(13.0) | 28.3 (13.5) | 27.6(16.4) | 2.2 (2,177).111 |
| Illness (yrs) | |||||
| CPZE total** | 5.0 (7.9) | 5.3 (8.2) | 4.7 (7.9) | 4.6 (7.3) | .1 (2,140) .917 |
| N (%) | N (%) | N (%) | N (%) | Chi-square test (df); p-value | |
| Race | |||||
| Non-Caucasian | 45 (22%) | 23 (23%) | 14 (17%) | 8 (42%) | 5.5 (2); .065 |
| Caucasian | 156 (78%) | 78 (77%) | 67 (83%) | 11 (58%) | |
| Hispanic | |||||
| Non-Hispanic | 181 (90%) | 95 (94%) | 68 (84%) | 18 (95%) | 5.6 (2); .060 |
| Hispanic | 20 (10%) | 6 (6%) | 13 (16%) | 1 (5%) | |
| Gender | |||||
| Female | 103 (51%) | 51 (50%) | 39 (48%) | 13 (68%) | 2.6 (2); .276 |
| Male | 98 (49%) | 50 (50%) | 42 (52%) | 6 (32%) | |
| Schizoaffective | 57 (28.4%) | 26 (32.1%) | (29) 28.7% | 2 (10.5%) | 3.6 (2),.171 |
| Living Situation | |||||
| Independent | 107 (53%) | 70 (69%) | 34 (42%) | 3 (16%) | 25.3 (2);<.001 |
| Board and Care | 94 (47%) | 31 (31%) | 47 (58%) | 16 (84%) | |
*
Positive and Negative Syndrome Scale
**
Chlorpromazine Equivalent dosage